326 resultados para Gallen-Kallela Akseli


Relevância:

20.00% 20.00%

Publicador:

Relevância:

10.00% 10.00%

Publicador:

Resumo:

To compare the distributions of patients with clinical-pathological subtypes of luminal B-like breast cancer according to the 2011 and 2013 St. Gallen International Breast Cancer Conference Expert Panel. We studied 142 women with breast cancer who were positive to estrogen receptor and had been treated in São Paulo state, southeast Brazil. The expression of the following receptors was assessed by immunohistochemistry: estrogen, progesterone (PR) and Ki-67. The expression of HER-2 was measured by fluorescent in situ hybridization analysis in tissue microarray. There were 29 cases of luminal A breast cancers according to the 2011 St. Gallen International Breast Cancer Conference Expert Panel that were classified as luminal B-like in the 2013 version. Among the 65 luminal B-like breast cancer cases, 29 (45%) were previous luminal A tumors, 15 cases (20%) had a Ki-67 >14% and were at least 20% PR positive and 21 cases (35%) had Ki-67 >14% and more than 20% were PR positive. The 2013 St. Gallen consensus updated the definition of intrinsic molecular subtypes and increased the number of patients classified as having luminal B-like breast cancer in our series, for whom the use of cytotoxic drugs will probably be proposed with additional treatment cost.

Relevância:

10.00% 10.00%

Publicador:

Resumo:

Migraine is a common neurovascular brain disorder that is manifested in recurrent episodes of disabling headache. The aim of the present study was to compare the prevalence and heritability of migraine across six of the countries that participate in GenomEutwin project including a total number of 29,717 twin pairs. Migraine was assessed by questionnaires that differed between most countries. It was most prevalent in Danish and Dutch females (32% and 34%, respectively), whereas the lowest prevalence was found in the younger and older Finnish cohorts (13% and 10%, respectively). The estimated genetic variance (heritability) was significant and the same between sexes in all countries. Heritability ranged from 34% to 57%, with lowest estimates in Australia, and highest estimates in the older cohort of Finland, the Netherlands, and Denmark. There was some indication that part of the genetic variance was non-additive, but this was significant in Sweden only. In addition to genetic factors, environmental effects that are non-shared between members of a twin pair contributed to the liability of migraine. After migraine definitions are homogenized among the participating countries, the GenomEUtwin project will provide a powerful resource to identify the genes involved in migraine.

Relevância:

10.00% 10.00%

Publicador:

Resumo:

Las características del hábito tabáquico en los estudiantes de la División de Ciencias de la Salud de la Universidad de Barcelona han sido estudiadas en este trabajo. Durante el Curso Académico 1988-89, 382 alumnos han sido entrevistados individualmente en relación al tabaquismo, mediante el cuestionario utilizado habitualmente por el Departamento de Sanidad y Segundad Social de la Generalidad de Cataluña (España), con las modificaciones más oportunas para este colectivo específico. Asimismo se ha recogido información relacionada con la influencia de los estudios universitarios en el hábito de fumar, la autorización de la publicidad y la eficacia de los programas y campañas de lucha antitabaco desarrollados por las Administraciones públicas. La prevalencia de tabaquismo ha sido del 40,8% (29,8% de fumadores habituales y 11% de fumadores ocasionales). Hay que remarcar que los estudios relacionados con la salud no parecen influir de forma destacada en el hábito de los estudiantes, siendo el entorno cultural y social los factores que tienen un papel más determinante en este sentido. Como conclusión final señalar que, para disminuir la prevalencia de tabaquismo en este importante colectivo, hay que instaurar programas educativos a nivel de la escolarización pre-universitaria (bachillerato unificado polivalente y curso de orientación universitaria), e introducir modificaciones en los futuros planes de estudio de las profesiones sanitarias, de manera que los contenidos relacionados con el tabaco sean más motivadores para los alumnos.

Relevância:

10.00% 10.00%

Publicador:

Resumo:

Dissertação apresentada para obtenção do Grau de Doutor em Engenharia Electrotécnica e de Computadores – Sistemas Digitais e Percepcionais pela Universidade Nova de Lisboa, Faculdade de Ciências e Tecnologia

Relevância:

10.00% 10.00%

Publicador:

Resumo:

[Table des matières] Introduction. 2 Stratégies de prévention dans d'autres régions. 3. Australie (Australian Better Health Initiative 2006-2010). 4. Royaume-Uni. 5. Suisse. 5.1 En résumé ... 5.2 Vers une loi fédérale (?) 5.3 Suisse : synopsis. 6. Saint-Gall. 6.1 Poids corporel sain pour les enfants. 6.2 Santé au travail. 6.3 Dépendances. 6.4 Prévention et promotion de la santé dans les communes. 6.5 Saint-Gall : synopsis. 7. Valais. 8. Tessin. 8.1 Canton du Tessin : Synopsis I (programme général). 8.2 Canton du Tessin : Synopsis II (activités en cours). Annexe 1 : 21 buts de santé pour la Suisse (Santé Publique Suisse). Annexe 2 : 7 thèses sur la nouvelle réglementation de la prévention et de la promotion de la santé en Suisse (Office fédéral de la santé publique).

Relevância:

10.00% 10.00%

Publicador:

Resumo:

Le monitoring de la problématique du cannabis en Suisse constitue un ensemble de travaux qui permet un suivi de la situation au niveau national et dont la mise en oeuvre est le fait d'un consortium d'instituts. Ce monitoring comprend l'étude présentée dans ce rapport, l'étude sentinelle. Elle s'intéresse à l'évolution de la situation en matière de cannabis ainsi qu'à la gestion de cette situation au niveau local. Ainsi, les observations relevées par des professionnels de terrain dans différents domaines (santé/social, école/formation professionnelle, police/justice) et dans quatre cantons suisses (St Gall, Tessin, Vaud, Zurich), dits "sentinelles", sont récoltées et analysées annuellement.

Relevância:

10.00% 10.00%

Publicador:

Resumo:

Background: The prevalence of a low bone mineral density (T-score <-1 SD) in postmenopausal women with a fragility fracture may vary from 70% to less than 50%. In one study (Siris ES. Arch Intern Med. 2004;164:1108-12), the prevalence of osteoporosis was very low at 6.4%. The corresponding values in men are rarely reported. Methods: In a nationwide Swiss survey, all consecutive patients aged 50+ presenting with one or more fractures to the emergency ward, were recruited by 8 participating hospitals (University Hospitals: Basel, Bern, and Lausanne; cantonal hospitals: Fribourg, Luzern, and St Gallen; regional hospitals: Estavayer and Riaz) between 2004 and 2006. Diagnostic workup was collected for descriptive analysis. Results: 3667 consecutive patients with a fragility fracture, 2797 women (73.8 ± 11.6 years) and 870 men (70.0 ± 12.1 years), were included. DXA measurement was performed in 1152 (44%) patients. The mean of the lowest T-score values was -2.34 SD in women and -2.16 SD in men. In the 908 women, the prevalence of osteoporosis and osteopenia according to the fracture type was: sacrum (100%, 0%), rib (100%, 0%), thoracic vertebral (78%, 22%), femur trochanter (67%, 26%), pelvis (66%, 32%), lumbar vertebral (63%, 28%), femoral neck (53%, 34%), femur shaft (50%, 50%), proximal humerus (50%, 34%), distal forearm (41%, 45%), tibia proximal (41%, 31%), malleolar lateral (28%, 46%), malleolar median (13%, 47%). The corresponding percentages in the 244 men were: distal forearm (70%, 19%), rib (63%, 11%), pelvis (60%, 20%), malleolar median (60%, 32%), femur trochanter (48%, 31%), thoracic vertebral (47%, 53%), lumbar vertebral (43%, 36%), proximal humerus (40%, 43%), femoral neck (28%, 55%), tibia proximal (26%, 36%), malleolar lateral (18%, 56%). Conclusion: The probability of underlying osteoporosis or osteopenia in men and women aged 50+ who experienced a fragility fracture was beyond 75% in fractures of the sacrum, pelvis, spine, femur, proximal humerus and distal forearm. The medial and lateral malleolar fractures had the lowest predictive value in women, not in men.

Relevância:

10.00% 10.00%

Publicador:

Resumo:

BACKGROUND: In Switzerland, intravenous drug use (IDU) accounts for 80% of newly acquired hepatitis C virus (HCV) infections. Early HCV treatment has the potential to interrupt the transmission chain and reduce morbidity/mortality due to decompensated liver cirrhosis and hepatocellular carcinoma. Nevertheless, patients in drug substitution programs are often insufficiently screened and treated. OBJECTIVE/METHODS: With the aim to improve HCV management in IDUs, we conducted a cross sectional chart review in three opioid substitution programs in St. Gallen (125 methadone and 71 heroin recipients). Results were compared with another heroin substitution program in Bern (202 patients) and SCCS/SHCS data. RESULTS: Among the methadone/heroin recipients in St. Gallen, diagnostic workup of HCV was better than expected: HCV/HIV-status was unknown in only 1% (2/196), HCV RNA was not performed in 9% (13/146) of anti-HCV-positives and the genotype missing in 15% (12/78) of HCV RNA-positives. In those without spontaneous clearance (two thirds), HCV treatment uptake was 23% (21/91) (HIV-: 29% (20/68), HIV+: 4% (1/23)), which was lower than in methadone/heroin recipients and particularly non-IDUs within the SCCS/SHCS, but higher than in the, mainly psychiatrically focussed, heroin substitution program in Bern (8%). Sustained virological response (SVR) rates were comparable in all settings (overall: 50%, genotype 1: 35-40%, genotype 3: two thirds). In St. Gallen, the median delay from the estimated date of infection (IDU start) to first diagnosis was 10 years and to treatment was another 7.5 years. CONCLUSIONS: Future efforts need to focus on earlier HCV diagnosis and improvement of treatment uptake among patients in drug substitution programs, particularly if patients are HIV-co-infected. New potent drugs might facilitate the decision to initiate treatment.